Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Publishes List Of Pathogen Threats To Rouse Drug Developers

Executive Summary

The World Health Organisation has released a list of 12 bacteria it says pose the greatest threat to human health as a way of urging governments and the drug development industry to incentivize and launch an R&D response against the increasing global issue of antibiotic resistance.

You may also be interested in...



AMR Roundtable Part 2: The Need For Patient Perspectives To Reinforce Urgency Of Antimicrobial Drug Development

Scrip spoke with the CEOs of Zavante and Amplyx as well as a BARDA official during a roundtable discussion at BIO about the challenges of antimicrobial drug development. This second part of the roundtable centers on the lack of patient advocates in the area of antimicrobial-resistant infections.

Critical Clinical Trial Updates Expected in 3Q

Ten clinical trial data readouts to watch for in the third quarter of 2017 that are expected to shift stocks and potentially change standard of care options in some disease areas.

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel